…
Principal Technologies Inc. is a private equity firm specializing in growth capital and middle market investments and direct equity investments. It invests in form of equity related and secured convertible debt. It invests in healthcare technology companies and assets. It seeks to identify technologies with IP capable of improving patient outcomes by enhancing medical treatment quality and efficiency, cost-efficiency, optimization of the patient pathway, and implementation of point of care technologies. The firm seeks to invest globally privately. Principal Technologies Inc. was incorporated in 2018 and is headquartered in Vancouver, Canada and has additional office in Vienna, Austria.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Principal Technologies Inc, listed under ticker PTEC.V, has limited publicly available disclosure and its core operations and product lines are not clearly described in public filings. Because of that scarcity of information, investors may find potential exposure to an early-stage issuer attractive if it achieves commercial traction, but specific long-term growth drivers are not confirmed by public sources.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Income before tax | -4.20M | -1.54M | -1.02M | -1.31M | -0.44M |
| Minority interest | -0.01M | -0.04M | -0.00M | -0.00M | - |
| Net income | -4.24M | -1.62M | -1.03M | -1.35M | -0.44M |
| Selling general administrative | 4.01M | 1.99M | 1.31M | 1.66M | 0.45M |
| Reconciled depreciation | 0.05M | 0.05M | 0.03M | 0.02M | - |
| Ebit | - | - | - | - | -0.39M |
| Ebitda | - | - | - | -1.28M | -0.45M |
| Operating income | -4.18M | -1.51M | -1.01M | -1.34M | -0.45M |
| Interest expense | 0.02M | 0.03M | 0.01M | 0.01M | 0.00M |
| Tax provision | 0.02M | 0.03M | 0.01M | 0.04M | - |
| Interest income | 0.02M | 0.02M | 0.00M | 0.00M | 0.00M |
| Net interest income | 0.00M | -0.01M | -0.01M | -0.01M | 0.00M |
| Total revenue | 0.37M | 0.66M | 0.43M | 0.34M | 0.00M |
| Total operating expenses | 4.55M | 2.18M | 1.43M | 1.68M | 0.45M |
| Total other income expense net | -0.02M | -0.02M | -0.01M | 0.04M | - |
| Net income from continuing ops | -4.22M | -1.58M | -1.03M | -1.35M | -0.44M |
| Net income applicable to common shares | - | - | - | - | -0.44M |
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Total assets | 1.55M | 1.51M | 0.73M | 0.76M | 1.44M |
| Total liab | 1.36M | 0.44M | 0.53M | 0.31M | 0.07M |
| Total stockholder equity | 0.09M | 1.01M | 0.15M | 0.41M | 1.36M |
| Other current liab | 0.47M | - | - | - | 0.07M |
| Common stock | - | - | - | - | 1.91M |
| Capital stock | 7.14M | 4.51M | 2.50M | 1.93M | 1.91M |
| Retained earnings | -8.94M | -4.57M | -2.95M | -1.92M | -0.57M |
| Other assets | - | - | - | - | 0.15M |
| Cash | 1.06M | 0.85M | 0.16M | 0.35M | 1.29M |
| Total current liabilities | 1.35M | 0.39M | 0.48M | 0.25M | 0.07M |
| Short long term debt | 0.14M | - | - | - | - |
| Other stockholder equity | - | - | - | - | 0.03M |
| Total current assets | 1.20M | 1.13M | 0.37M | 0.43M | 1.29M |
| Long term investments | 0.26M | 0.26M | 0.26M | 0.26M | - |
| Net tangible assets | - | - | - | - | 1.36M |
| Net receivables | 0.04M | 0.11M | 0.12M | 0.05M | 0.00M |
| Accounts payable | 0.70M | - | - | - | - |
| Non current assets total | 0.34M | 0.38M | 0.35M | 0.33M | 0.15M |
| Capital lease obligations | 0.05M | 0.09M | 0.08M | 0.07M | - |
| Breakdown | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
| Investments | - | -0.07M | -0.00M | -0.26M | -0.15M |
| Change to liabilities | - | - | - | - | 0.07M |
| Total cashflows from investing activities | - | - | - | - | -0.15M |
| Net borrowings | 0.98M | -0.02M | - | - | - |
| Total cash from financing activities | 3.24M | 2.38M | 0.26M | -0.01M | 0.19M |
| Change to operating activities | - | - | - | - | -0.00M |
| Net income | -4.24M | -1.62M | -1.03M | -1.35M | -0.44M |
| Change in cash | 0.20M | 0.70M | -0.19M | -0.94M | -0.35M |
| Begin period cash flow | 0.85M | 0.16M | 0.35M | 1.29M | 1.64M |
| End period cash flow | 1.06M | 0.85M | 0.16M | 0.35M | 1.29M |
| Total cash from operating activities | -3.03M | -1.64M | -0.47M | -0.64M | -0.38M |
| Issuance of capital stock | 1.80M | 2.43M | 0.30M | 0.00M | 0.18M |
| Depreciation | 0.05M | 0.05M | 0.03M | 0.02M | - |
| Other cashflows from investing activities | - | - | - | - | -0.15M |
| Change to account receivables | - | - | - | - | -0.00M |
| Capital expenditures | 0.01M | 0.07M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.45M | -0.16M | 0.18M | 0.29M | 0.07M |
| Stock based compensation | 0.65M | 0.03M | 0.35M | 0.40M | - |
| Other non cash items | 0.00M | 0.03M | 0.01M | 0.01M | - |
| Free cash flow | -3.04M | -1.71M | -0.47M | -0.64M | -0.38M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PTEC Principal Technologies Inc |
- -% |
0.32 | - | - | 62.75 | 355.42 | 72.08 | -0.81 |
| NURS Hydreight Technologies Inc |
-0.04 1.32% |
2.98 | 406.00 | 25.91 | 7.85 | 20.38 | 7.45 | 109.02 |
| ADK Diagnos Inc |
-0.01 1.41% |
0.35 | - | 10.00 | 411.24 | 18.74 | 389.06 | -6.16 |
| NXG NexgenRX Inc. |
- -% |
0.66 | 39.00 | 32.68 | 1.55 | 4.64 | 1.39 | 7.84 |
| CHS Comprehensive Healthcare Systems Inc |
- -% |
0.33 | - | - | 4.44 | 13.23 | 3.83 | 26.88 |
Principal Technologies Inc. is a private equity firm specializing in growth capital and middle market investments and direct equity investments. It invests in form of equity related and secured convertible debt. It invests in healthcare technology companies and assets. It seeks to identify technologies with IP capable of improving patient outcomes by enhancing medical treatment quality and efficiency, cost-efficiency, optimization of the patient pathway, and implementation of point of care technologies. The firm seeks to invest globally privately. Principal Technologies Inc. was incorporated in 2018 and is headquartered in Vancouver, Canada and has additional office in Vienna, Austria.
700 W Georgia Street, Vancouver, BC, Canada, V6C 1H2
587 225 2599
| Name | Title | Year Born |
|---|---|---|
| Mr. Gerald Trent | Group CEO, Pres & Director | 1977 |
| Mr. Frank Stronach | CFO, Corp. Sec. & Director | 1951 |
| Mr. Gerald Trent | Group CEO, President & Director | 1978 |
| Mr. Peter L. A. McKeown C.A., CA | CFO & Corporate Secretary | NA |
| Ilse Christa Eder | CEO of E&E CRO Consulting | NA |
| Mr. Peter L. A. McKeown C.A. | Chief Financial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.